Market Place
Sourcing Support
NICE recommends Takeda’s Ninlaro triplet regimen
20 Jan 2023 //
PHARMATIMES
NICE recommends all-oral treatment for multiple myeloma
19 Jan 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
Active Biotech Begins Dosing in comb. part of phase Ib/IIa study of tasquinimod
07 Feb 2022 //
GLOBENEWSWIRE
Takeda Announces Result of Phase 3 Clinical Trial to Evaluate NINLARO (ixazomib)
11 Sep 2020 //
BUSINESS WIRE
Takeda`s ixazomib comes up short in first-line multiple myeloma study
09 Sep 2020 //
SEEKINGALPHA
MHLW Revokes Ninlaro’s Sakigake Status for AL Amyloidosis
26 Jun 2020 //
JIHO
Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO™
12 Jun 2020 //
PRESS RELEASE
Takeda`s Ninlaro combo fails to hit main goal
11 Mar 2020 //
PHARMAFILE
Takeda scores a win for Ninlaro
08 Nov 2019 //
FIERCE PHARMA
Declaring topline PhIII win, Takeda revives blockbuster hopes for its troubled multiple myeloma drug
08 Nov 2019 //
BUSINESSWIRE
EMA & FDA Historically Agree on Just About Every New Drug Approval
16 Aug 2019 //
RAPS
EMA & FDA Historically Agree on Just About Every New Drug Approval
16 Aug 2019 //
RAPS
Takeda sets December deadline for U.S. employees` Boston move
27 Jun 2019 //
FIERCE PHARMA
Takeda swings and misses with Ninlaro in AL amyloidosis, calls off phase 3 trial
07 Jun 2019 //
FIERCE PHARMA
Takeda suffers another setback in its quest to expand myeloma drug’s reach
06 Jun 2019 //
ENDPTS
J&J eyes Darzalex convenience, safety boost with subcutaneous win
05 Jun 2019 //
FIERCE PHARMA
Takeda to Showcase Growing Pipeline & Diversified Portfolio of Oncology Products
16 May 2019 //
BUSINESSWIRE
Takeda hits FDA snag on Ninlaro, but its growth still helps drive revenue hike
01 Feb 2019 //
FIERCE PHARMA
Takeda to Present Data on Wide Array of Treatment Needs for Blood Cancers
02 Nov 2018 //
BUSINESSWIRE
Takeda`s Ninlaro (ixazomib citrate) Receives Conditional approval in Europe
20 Oct 2018 //
EMA
Bristol-Myers to sell Opdivo in China at half-price: report
22 Aug 2018 //
FIERCE PHARMA
China Unveils Cancer Drugs for Medical Insurance Access Negotiation
21 Aug 2018 //
BIOCENTURY
Lack of blockbuster candidates at Takeda? Shire has it covered
01 Aug 2018 //
FIERCE PHARMA
Immunology keeps Shire figures solid as Takeda takeover nears
31 Jul 2018 //
PM LIVE
Phase 3 Trial of NINLARO (ixazomib) as Maintenance Therapy Met Primary Endpoint
11 Jul 2018 //
BUSINESSWIRE
Takeda can`t sway NICE on oral myeloma therapy Ninlaro
07 Sep 2017 //
PMLIVE
Chinese courts call for death penalty for researchers who commit fraud
23 Jun 2017 //
STATNEWS
Takeda breaks ground on $45m Ninlaro plant in Ireland
07 Jun 2017 //
IN PHARMATECHNOLOGIST
Takeda, sporting a new-look portfolio, revs for Roche battle in ALK lung cancer
05 Jun 2017 //
FIERCE PHARMA
Takeda Shells Out Whopping $5.2B & its Fledgling Med Brigatinib
10 Jan 2017 //
FIERCE PHARMA
Takeda Gets EU Nod For Ninlaro (ixazomib citrate)
07 Dec 2016 //
EMA
Conditional EU Nod for Takeda’s Ninlaro
02 Dec 2016 //
PHARMATIMES
J&J`s Darzalex leaps ahead in multiple myeloma lineup with new FDA approval
22 Nov 2016 //
FIERCE PHARMA
Takeda CEO says new myeloma drug Ninlaro will be ` bigger than Velcade`
31 Oct 2016 //
FIERCE PHARMA
Reorg, new meds help Takeda crawl out of profit hole
11 May 2016 //
FIERCE PHARMA
Independent group finds multiple myeloma drugs too costly in U.S
07 May 2016 //
REUTERS
Takeda in myeloma research drive
13 Jan 2016 //
PHARMAFILE
Ash Stevens to make API for Takeda`s new oral blood cancer drug
24 Nov 2015 //
IN-PHARMA TECHNOLOGIST
Takeda`s `breakthrough` Velcade heir wins early FDA approval in myeloma
20 Nov 2015 //
FIERCE BIOTECH
US priority review for Takeda`s multiple myeloma drug
10 Sep 2015 //
PM LIVE
EMA accepts Takeda`s ixazomib MAA to treat patients with relapsed/refractory multiple myeloma
24 Aug 2015 //
PHARMABIZ
Takeda rolls toward EU approval with its heir to Velcade
22 Aug 2015 //
FIERCE BIOTECH
Takeda files ixazomib in the US for multiple myeloma
15 Jul 2015 //
PHARMA TIMES
